Across TCGA pan-cancer cohorts, EEF1AKMT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EEF1AKMT2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EEF1AKMT2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EEF1AKMT2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where EEF1AKMT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.177	1.000	.038	18	view →
LSCC	OS	Quartile	II,III,IV	0.947	0.525	.001	17	view →
LUAD	DFS	Median	III,IV	0.829	0.341	.017	3	view →
PDAC	OS	Median	IV	0.222	0.973	.038	3	view →
CCRCC	DFS	Median	All	0.750	0.231	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: EEF1AKMT2 tumor-vs-normal RNA expression · all EEF1AKMT2 data types